Petter Olsson

Publications
CV
Public outreach and news

Articles

Article: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE. 2022;10(12):3156-3162
Allergic Fungal Rhinosinusitis: The Role and Expectations of Biologics
Luong AU; Chua A; Alim BM; Olsson P; Javer A
Article: ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY. 2021;17(1):55
HealthSWEDE: costs with sublingual immunotherapy-a Swedish questionnaire study
Olsson P; Skroder C; Ahlbeck L; Hjalte F; Welin K-O; Westin U; Andersson M; Ahlstrom-Emanuelsson C; Cardell L-O
Article: RESPIRATORY RESEARCH. 2020;21(1):93
Impact of baseline symptoms and health status on COPD exacerbations in the FLAME study
Mackay AJ; Kostikas K; Roche N; Frent S-M; Olsson P; Pfister P; Gupta P; Patalano F; Banerji D; Wedzicha JA
Article: RESPIROLOGY. 2020;25(4):393-400
Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long-acting bronchodilator-naive COPD patients: A pooled analysis
Muro S; Yoshisue H; Kostikas K; Olsson P; Gupta P; Wedzicha JA
Article: INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE. 2019;14:995-1008
Impact of COPD diagnosis timing on clinical and economic outcomes: the ARCTIC observational cohort study
Larsson K; Janson C; Stallberg B; Lisspers K; Olsson P; Kostikas K; Gruenberger J-B; Gutzwiller FS; Uhde M; Jorgensen L; Johansson G
Article: RESPIROLOGY. 2018;23(12):1152-1159
Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trial
Frith PA; Ashmawi S; Krishnamurthy S; Gurgun A; Hristoskova S; Pilipovic V; Hamann AM; Backer A; Olsson P; Kostikas K; Diaz DV
Article: RESPIRATORY RESEARCH. 2018;19(1):172
Identifying the associated risks of pneumonia in COPD patients: ARCTIC an observational study
Janson C; Johansson G; Stallberg B; Lisspers K; Olsson P; Keininger DL; Uhde M; Gutzwiller FS; Jorgensen L; Larsson K
Article: INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE. 2018;13:1125-1134
Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study
Vogelmeier CF; Chapman KR; Miravitlles M; Roche N; Vestbo J; Thach C; Banerji D; Fogel R; Patalano F; Olsson P; Kostikas K; Wedzicha JA
Article: RESPIRATORY RESEARCH. 2017;18(1):206
Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population
Bjermer L; van Boven JFM; Costa-Scharplatz M; Keininger DL; Gutzwiller FS; Lisspers K; Mahon R; Olsson P; Roche N
Article: AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. 2017;195(9):1189-1197
Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment Data from the FLAME Trial
Roche N; Chapman KR; Vogelmeier CF; Herth FJF; Thach C; Fogel R; Olsson P; Patalano F; Banerji D; Wedzicha JA
Journal article: PNEUMOLOGIE. 2017;71(S 01):s1-s125
Einmal täglich Indacaterol/Glycopyrronium (IND/GLY) reduziert COPD Exazerbationen im Vergleich zu zweimal täglich Salmeterol/Fluticason (SFC) in COPD Patienten mit mindestens einer Exazerbation im Vorjahr: die FLAME Studie
Vogelmeier C; Wedzicha J; Chapman K; Ayers T; FowlerTaylor A; Thach C; Olsson P; Shrinivasan A; Fogel R; Patalano F; Banerji D
Article: ACTA OTO-LARYNGOLOGICA. 2016;136(8):852-859
Treatment of idiopathic rhinitis with kinetic oscillations - a multi-centre randomized controlled study
Ehnhage A; Johnsson PS; Ahlstrom-Emanuelsson C; Andersson M; Knutsson J; Lien J; Norlander T; Olsson P; Friis-Liby J-E; Holmstrom M
Article: NPJ PRIMARY CARE RESPIRATORY MEDICINE. 2016;26:15082
TOTALL: high cost of allergic rhinitis-a national Swedish population-based questionnaire study
Cardell L-O; Olsson P; Andersson M; Welin K-O; Svensson J; Tennvall GR; Hellgren J
Journal article: PNEUMOLOGIE. 2015;69(S 01)
QVA149 reduziert das Risiko moderater bis schwerer Exazerbationen im Vergleich zu unverblindetem Tiotropium bei Patienten mit schwerer COPD: Die SPARK-Studie
Ficker J; Wedzicha W; Decramer M; Olsson P; Chen H; Fogel R; Banerji D
Article: ACTA OTO-LARYNGOLOGICA. 2013;133(9):939-943
Effects of FESS and additional fluticasone propionate nasal drops on psychological well-being in nasal polyposis with asthma
Nordin S; Olsson P; Blomqvist EH; Stjarne P; Ehnhage A
Article: PRIMARY CARE RESPIRATORY JOURNAL. 2012;21(4):412-418
Cost-effectiveness of mometasone furoate nasal spray in the treatment of acute rhinosinusitis
Svensson J; Lundberg J; Olsson P; Stjarne P; Tennvall GR
Article: PRIMARY CARE RESPIRATORY JOURNAL. 2012;21(2):174-179
High costs and burden of illness in acute rhinosinusitis: real-life treatment patterns and outcomes in Swedish primary care
Stjarne P; Odeback P; Stallberg B; Lundberg J; Olsson P
Article: ACTA OTO-LARYNGOLOGICA. 2011;131(8):826-832
Effects of smell loss on daily life and adopted coping strategies in patients with nasal polyposis with asthma
Nordin S; Blomqvist EH; Olsson P; Stjarne P; Ehnhage A
Article: RHINOLOGY. 2010;48(3):325-330
Quality of life is improved by endoscopic surgery and fluticasone in nasal polyposis with asthma
Olsson P; Ehnhage A; Nordin S; Stjarne P
Journal article: OTOLARYNGOLOGY-HEAD AND NECK SURGERY. 2010;143(S2):p130-p131
Improved Asthma and Olfaction Parameters One Year Post‐ESS
Stjarne P; Olsson P
Article: RHINOLOGY. 2010;48(2):150-155
Endoscopic Sinus Surgery improves olfaction in nasal polyposis, a multi-center study
Olsson P; Stjarne P
Article: ALLERGY. 2009;64(11):1663-1670
Desloratadine relieves nasal congestion and improves quality-of-life in persistent allergic rhinitis
Holmberg K; Tonnel A-B; Dreyfus I; Olsson P; Cougnard J; Mesbah K; Devillier P
Article: ALLERGY. 2009;64(5):762-769
Functional endoscopic sinus surgery improved asthma symptoms as well as PEFR and olfaction in patients with nasal polyposis
Ehnhage A; Olsson P; Kolbeck K-G; Skedinger M; Dahlen B; Alenius M; Stjarne P
Article: RESPIRATORY MEDICINE. 2008;102(10):1406-1411
Comparable morning versus evening administration of once-daily mometasone furoate dry powder inhaler
Zetterstrom O; Dahl R; Lindqvist A; Olsson P
Journal article: OTOLARYNGOLOGY-HEAD AND NECK SURGERY. 2007;137(S2):p273
P188: Mometasone Furoate Prolongs Post‐FESS Return of Nasal Polyps
Stjärne P; Olsson P
Article: ACTA OTO-LARYNGOLOGICA. 2003;123(1):75-80
Prevalence of self-reported allergic and non-allergic rhinitis symptoms in Stockholm:: Relation to age, gender, olfactory sense and smoking
Olsson P; Berglind N; Bellander T; Stjärne P
Show more

All other publications

Preprint: AUTHOREA PREPRINTS. 2024
Omalizumab for the Treatment of Allergic Rhinitis: A Systematic Review and Meta-Analysis
Tsabouri S; Ntritsos G; Koskeridis F; Evangelou E; Olsson P; Kostikas K
Review: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE. 2022;10(10):2570-2578
The Role of Omalizumab in NSAID-Exacerbated Respiratory Disease: A Narrative Review
Taniguchi M; Heffler E; Olze H; White A; Corte-Real J; Olsson P; Lazarewicz S
Review: RHINOLOGY. 2021;59(6):501-510
Omalizumab for the treatment of allergic rhinitis: a systematic review and meta-analysis
Tsabouri S; Ntritsos G; Koskeridis F; Evangelou E; Olsson P; Kostikas K
Preprint: RESEARCH SQUARE. 2020
Research HealthSWEDE: Costs With Sublingual Immunotherapy - A Swedish Questionnaire Study
Olsson P; Sköder C; Ahlbeck L; Hjalte F; Welin K-O; Westin U; Andersson M; Emanuelsson CA; Cardell L-O
Meeting abstract: EUROPEAN RESPIRATORY JOURNAL. 2019;54:PA2546
Omalizumab in the real-world: systematic review of asthma control outcomes reported by patients
Nissen F; Humbert M; Gibson P; Kostikas K; Jaumont X; Olsson P; Alvares L; Bousquet J
Conference publication: EUROPEAN RESPIRATORY JOURNAL. 2018;52:pa4387
Baseline symptom burden and dual bronchodilator response in the FLAME study
Mackay A; Kostikas K; Frent S-M; Olsson P; Pfister P; Gupta P; Patalano F; Banerji D; Wedzicha JA
Meeting abstract: EUROPEAN RESPIRATORY JOURNAL. 2018;52:PA4376
Indacaterol/glycopyrronium vs tiotropium or glycopyrronium in treatment naive COPD patients: a pooled analysis
Muro S; Yoshisue H; Mackay AJ; Kostikas K; Olsson P; Gupta P; Wedzicha JA
Letter: AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. 2018;197(7):968-969
The Significance of Eosinophilic Inflammation in Chronic Obstructive Pulmonary Disease Reply
Roche N; Chapman KR; Vogelmeier CF; Herth FJF; Thach C; Fogel R; Olsson P; Patalano F; Banerji D; Wedzicha JA
Letter: AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. 2017;196(9):1230-1231
What Should Be the Cutoff Value of Blood Eosinophilia as a Predictor of Inhaled Reply
Roche N; Chapman KR; Vogelmeier CF; Herth FJF; Thach C; Fogel R; Olsson P; Patalano F; Banerji D; Wedzicha JA
Conference publication: EUROPEAN RESPIRATORY JOURNAL. 2017;50:pa1802
Delayed time to first and subsequent exacerbations independent of season with indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone (SFC): the FLAME study
Chapman K; Kostikas K; Olsson P; Thach C; Patalano F; Fogel R; Banerji D
Conference publication: EUROPEAN RESPIRATORY JOURNAL. 2017;50:pa1075
Respiratory safety profile of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC): results from the FLAME study
Wedzicha J; Vogelmeier CF; Ayers T; Olsson P; Patalano F; Thach C; Fogel R; Banerji D
Meeting abstract: EUROPEAN RESPIRATORY JOURNAL. 2017;50:PA939
Indacaterol/glycopyrronium (IND/GLY) is cost-effective compared with salmeterol/fluticasone (SFC) in Swedish chronic obstructive pulmonary disease (COPD) patients
Bjermer L; van Boven JFM; Costa-Scharplatz M; Gutzwiller FS; Lisspers K; Mahon R; van der Molen T; Olsson P; Roche N; Burke C
Meeting abstract: EUROPEAN RESPIRATORY JOURNAL. 2017;50:PA936
Estimating the number of patients' needed to treat (NNT) with indacaterol/glycopyrronium to prevent COPD exacerbations: Results from the FLAME study
Bjermer L; Roche N; Gutzwiller FS; Olsson P; Patalano F; Thach C; Fogel R; Banerji D
Conference publication: EUROPEAN RESPIRATORY JOURNAL. 2016;48:pa991
Indacaterol/glycopyrronium (IND/GLY) reduces exacerbations compared with salmeterol/fluticasone (SFC) in various sub-groups from the FLAME study
Wedzicha J; Chapman K; FowlerTaylor A; Ayers T; Thach C; Olsson P; Fogel R; Patalano F; Banerji D
Meeting abstract: EUROPEAN RESPIRATORY JOURNAL. 2016;48:PA989
Once-daily indacaterol/glycopyrronium (IND/GLY) reduces all exacerbations compared with twice-daily salmeterol/fluticasone (SFC) in COPD patients with ≥ 1 exacerbation in the previous year: The FLAME study
Wedzicha J; Vogelmeier CF; Ayers T; FowlerTaylor A; Thach C; Olsson P; Fogel R; Patalano F; Banerji D
Meeting abstract: EUROPEAN RESPIRATORY JOURNAL. 2016;48:PA984
Effect of indacaterol/glycopyrronium versus salmeterol/fluticasone on hypothalamic pituitary-adrenal axis function in moderate-to-very severe COPD patients: Results from the FLAME study
Olsson P; Vogelmeier C; Chapman K; FowlerTaylor A; Ayers T; Thach C; Fogel R; Patalano F; Banerji D
Meeting abstract: EUROPEAN RESPIRATORY JOURNAL. 2016;48:PA3946
ICS and risk of pneumonia in Swedish COPD patients: The ARCTIC study
Janson C; Johansson G; Stallberg B; Lisspers K; Olsson P; Keininger D; Jorgensen L; Sobocki P; Larsson K
Meeting abstract: EUROPEAN RESPIRATORY JOURNAL. 2016;48:PA3933
Extent and impact of late vs early stage COPD diagnosis in the Swedish ARCTIC study
Larsson KA; Janson C; Stallberg B; Lisspers K; Olsson P; Kostikas K; Uhde M; Jorgensen L; Sobocki P; Johansson G
Meeting abstract: EUROPEAN RESPIRATORY JOURNAL. 2016;48:PA3927
Clinical and economic factors associated with spirometry-diagnosed COPD in the Swedish ARCTIC study
Johansson G; Larsson K; Stallberg B; Lisspers K; Olsson P; Gruenberger J-B; Jorgensen L; Sobocki P; Janson C
Meeting abstract: EUROPEAN RESPIRATORY JOURNAL. 2016;48:PA311
Cardiovascular (CV) safety of indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone combination (SFC) in moderate-to-very severe COPD patients with prior exacerbations: The FLAME study
Roche N; Olsson P; Vestbo J; FowlerTaylor A; Ayers T; Thach C; Clerkin K; Fogel R; Patalano F; Banerji D
Published conference paper: OTOLARYNGOLOGY-HEAD AND NECK SURGERY. 2012;146(5):834-841
One Year after Endoscopic Sinus Surgery in Polyposis: Asthma, Olfaction, and Quality-of-Life Outcomes
Ehnhage A; Olsson P; Kolbeck K-G; Skedinger M; Stjarne P
Conference publication: ALLERGY. 2011;66:243
Swedish observational study on symptoms, treatment patterns, quality of life and costs in acute rhinosinusitis (SOSAR)
Stjarne P; Stallberg B; Odeback P; Lundberg J; Olsson P
Corrigendum: ALLERGY. 2010;65(3):412
Desloratadine relieves nasal congestion and improves quality-of-life in persistent allergic rhinitis. (vol 64, pg 1663, 2009)
Holmberg K; Tonnel A-B; Dreyfus I; Olsson P; Cougnard J; Mesbah K
Published conference paper: ARCHIVES OF OTOLARYNGOLOGY - HEAD AND NECK SURGERY. 2009;135(3):296-302
Use of Mometasone Furoate to Prevent Polyp Relapse After Endoscopic Sinus Surgery
Stjaerne P; Olsson P; Alenius M
Thesis / dissertation: 2009
Prevalance of upper airway symptoms and aspects on treatment of nasal polyposis
Olsson, Petter
Letter: ACTA DERMATO-VENEREOLOGICA. 2009;89(3):305-307
A Randomized, Single-blind Comparison of the Efficacy, Tolerability and Cosmetic Acceptance of Propyless® or Fenuril® Treatment of Patients with Dry Skin
Faergemann J; Olsson P; Svensson A
Conference publication: ALLERGY. 2007;62:473-474
Efficacy of mometasone furoate nasal spray in the post-surgical treatment of nasal polyposis
Stjarne P; Olsson P
Show more

Employments

Affiliated to Research, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, 2023-2025

Degrees and Education

Degree Of Doctor Of Philosophy, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, 2009
University Medical Degree, Karolinska Institutet, 1993

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI